CAR-T boxed warnings: What comes next?

The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This decision follows an investigation into the new safety signal from postmarketing adverse event reports and clinical trials. 

In today’s episode, Fierce Pharma’s Angus Liu talks with regulatory experts Mwango Kashoki, M.D., and Steve Winitsky, M.D., to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line.

Return to Insights Center

Related Insights


Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022


Three ways to improve your chances that insurers will pay for a new CGT

Feb 18, 2021


Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023


New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023


CAR-T product development: an assessment of FDA’s final guidance for industry

Feb 27, 2024


Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021


CAR-T boxed warnings: regulatory precedents and opportunities

Feb 9, 2024


8 things you need to know about eCTDs in China

Jul 1, 2022


On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022


Chris Learn joins Parexel as Head of the Cell and Gene Center of Excellence

Apr 4, 2022


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022